Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Stellar Biotechnologies, Inc V.KLH

TSXV:KLH - Post Discussion

Stellar Biotechnologies, Inc > The reason share consolidations often don't work....
View:
Post by ledrog on Sep 11, 2015 4:03am

The reason share consolidations often don't work....

The reason you'll often see a stock struggle after a reverse split is because consolidating shares treats a sympton, not the disease itself.  The disease of course is a lack of investor confidence, that's what causes a company's share price to erode.  Over the past year KLH has seen its share price cut in half....that does not happen when investor confidence is high.  

Just turning 10 shares into 1 to boost the PPS.....does nothing to address the lack of investor confidence that caused the PPS to fall in the first place.
Comment by invertedhammer on Sep 11, 2015 11:45am
Could it be that investor confidence is high on KLH but also wise? That is to say... they believe it will succeed but it needs more time. If Stellar proves that they can control the growth and production of the KLH molecule on a mass scale and immunotherapies utilizing KLH in their clinical trials are proven successful and receive FDA approval... it's off to the races. No?
Comment by PaleRider22 on Sep 11, 2015 1:26pm
The Pacific Ocean does a fine job of producing the KLH molecule on a mass scale...
Comment by invertedhammer on Sep 11, 2015 4:53pm
No, the pacific ocean does just fine at providing a breeding ground for the Giant Keyhole Limpet; it doesn't extract the molecule from them nor does it monitor their existential risk. The feds do that. Sustainability is important! If everyone was allowed to walk down to the ocean and fill up their dump trucks with snails, I think we would risk extinction. Not a good outcome. Isn't that ...more  
Comment by waitingstill on Sep 11, 2015 10:38pm
invertedhammer - from what I have read, you are correct. I also think that Stellar has a facility to farm the mollusks as well. Somehow, they need to get the demand up for the molecule though.
Comment by invertedhammer on Sep 12, 2015 2:06am
Yes, I believe you're right, waitingstill. Stellar has a farming and production facility in operation already. However, from what I understand, Stellar, together with Ostiones Guerrero, will build a new facility just outside San Quintin, which will be conveniently located to where the limpets are captured. Apparently, Ostiones Guerrero is licensed to pull 12 metric tons of giant keyhole ...more  
Comment by ledrog on Sep 12, 2015 12:45am
That might happen....and it might not. However given the direction of the pps over the year or so...taking it from over $2 (pre RS) to under a buck now (again pre consolidation prices) it would seem your opinion is in oppostion to what the market has been saying.   There was a bit of a bump in anticipation of the Nasdaq application....but post split the PPS is heading down agian.  I ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities